Xin Lang Cai Jing·2025-10-29 07:22Core Viewpoint - Haiprime, a leading multinational pharmaceutical company, is benefiting from the depreciation of the RMB and has a strong focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2][3]. Company Overview - Haiprime was established in 1998 in Shenzhen and has both A and H share financing platforms. The company aims to provide high-quality, safe, and effective drugs and services to global patients [2]. - The main business segments of Haiprime include heparin raw materials, downstream low molecular weight heparin products, and biopharmaceutical CDMO services [7]. Financial Performance - For the first half of 2025, Haiprime reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - As of June 30, 2025, overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. Shareholder Information - As of June 30, 2025, Haiprime had 26,300 shareholders, a decrease of 7.29% from the previous period. The average circulating shares per person remained at 0 [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On October 29, Haiprime's stock price increased by 0.75%, with a trading volume of 41.3352 million yuan and a turnover rate of 0.28%, bringing the total market capitalization to 17.637 billion yuan [1].